Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus Pemetrexed and Anlotinib in Elderly EGFR-TKI Resistant NSCLC
NCT06277674Phase 2Recruiting
- Sponsor
- Guangzhou University of Chinese Medicine
- Start
- Nov 2023
- Primary completion
- Dec 2024
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in non-small cell lung cancer (NSCLC), sponsored by Guangzhou University of Chinese Medicine. Primary endpoint: Objective Response Rate up to 120 months. Started Nov 2023; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06277674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06277674.